
Isomorphic Labs raises $5bn from Sequoia and Greenoaks for AI drug design
THE SO WHAT
A $5B Series C just six months after a $2.1B raise puts Isomorphic Labs in a different league—AI drug discovery is being capitalized like a platform, not a biotech experiment. Pharma operators should assume these models will be strategic counterparties, not just tools, within this decade.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureHigher Rates Will Push Firms to Private Credit as Stress Rises
Higher rates pushing stressed borrowers toward private credit means more opaque, bespoke financing for capex-heavy plays — including AI infra. If you’re raising for large deployments, expect tighter public markets and start building relationships with private lenders early.
Startups & VentureCarlyle: We Don't Know the AI Model Yet as Credit Investors
When a top credit shop says it still doesn’t know the AI “model,” it’s flagging that cash-flow visibility on AI-heavy businesses is too low for cheap debt. Founders leaning on leverage for data centers or model training should expect tighter covenants, higher spreads, and more scrutiny on unit economics, not just growth narratives.
Startups & VentureGenerative media startup each::labs raises $7M seed co-led by the EBRD
A $7M seed for each::labs, co-led by the EBRD, shows institutional capital is now backing generative media infrastructure, not just creator tools. If you’re in media or marketing, plan for a world where content generation is cheap and the defensible layer is distribution, rights, and brand-safe workflows.
Startups & VentureAnthropic IPO Puts Wall Street’s Speculation Factory on Display
A frontier lab going public at this scale turns model bets into a liquid macro trade, not just a VC allocation. Operators should expect more volatility in vendor roadmaps and pricing as public-market expectations start steering AI balance sheets.